INVICORP^®

Invicorp^® is a highly safe and effective treatment for erectile dysfunction (ED), a condition that affects more than 100 million men worldwide. Invicorp^®, a combination of vasoactive intestinal peptide (VIP) and phentolamine mesylate (PMS), has shown excellent results in a wide range of patients, many of whom have failed on other therapies for the treatment of ED. VIP is a 28-amino-acid peptide found naturally in the male and female urogenital tracts, as well as in the central and peripheral nervous systems. It causes erection by binding to smooth-muscle receptors in the corpus cavernosum, inducing smooth-muscle relaxation and increased blood flow. In completed Phase III clinical trials conducted in the United Kingdom, Denmark, Ireland and Australia, Invicorp^® demonstrated outstanding efficacy and safety. The most frequently reported side effect was transient facial flushing, which typically subsided within minutes after use.  

Unlike many other ED therapies, Invicorp^® has no known contraindications. Other significant advantages include: rapid onset of erection after stimulation - typically within two-to-five minutes; the ability to induce an erection up to 2 1/2 hours after administration with natural termination of an erection after ejaculation, as well as efficacy in the treatment of organic ED. Invicorp^® is self-administered using a refillable syringe or a novel, yet uncomplicated, disposable drug delivery system, Reliaject^®, in each case using a super-fine 30 gauge needle for ease of administration (not possible with existing injectable therapies).

In a study of treatment options for Erectile Dysfunction, Decision Resources, Inc. indicated the medical community's enthusiasm for Invicorp^®. Among the findings, the study showed that intracavernous injection therapies will continue to be the most effective second-line treatments for moderate-to-severe ED (after oral therapies have been attempted and for patients for whom oral therapies are contraindicated, such as diabetics and hypertension sufferers). Based on physician enthusiasm, the treatment's high therapeutic index and advantages over current oral therapies, the study predicted that Invicorp^® could become the alternative therapy of choice.

Invicorp^® is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line ED treatment.  Invicorp^® is also expected to become first-line treatment for those with diabetes, heart disease and severe organic ED.

Invicorp^® has received marketing authorization in Denmark, which has been chosen as the Reference Member State for the Mutual Recognition Procedure in Europe, as well as in England. Additionally, Invicorp^® has been approved in New Zealand. 

Senetek has entered into exclusive licensing and collaborative marketing agreements for the commercialization of Invicorp^®, with Ardana BioSciences for the European market and with Plethora Solutions, for the U.S. market.